{"id":14238,"date":"2023-02-22T16:04:44","date_gmt":"2023-02-22T21:04:44","guid":{"rendered":"https:\/\/aafa.org\/?page_id=14238"},"modified":"2026-09-23T17:32:19","modified_gmt":"2026-09-23T21:32:19","slug":"asthma-allergies-continuing-education-cme","status":"publish","type":"page","link":"https:\/\/aafa.org\/programs\/education-programs\/asthma-allergies-continuing-education-cme\/","title":{"rendered":"Continuing Medical Education (CME) Programs"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Programs T- Hero Section&#8221; module_class=&#8221;hero tert&#8221; _builder_version=&#8221;4.25.1&#8243; _module_preset=&#8221;default&#8221; background_image=&#8221;https:\/\/aafa.org\/wp-content\/uploads\/2022\/07\/AAFA-Website_Tertiary_Programs.jpg&#8221; background_position=&#8221;top_right&#8221; custom_padding=&#8221;1%||1%||true|false&#8221; global_module=&#8221;1619&#8243; saved_tabs=&#8221;all&#8221; collapsed=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; background_enable_image=&#8221;off&#8221; background_size=&#8221;initial&#8221; background_position=&#8221;bottom_left&#8221; background_horizontal_offset=&#8221;0%&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;2%||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text admin_label=&#8221;Nav Parent Title&#8221; module_class=&#8221;tert-parent&#8221; _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; header_2_font=&#8221;|600|||||||&#8221; header_2_text_align=&#8221;left&#8221; header_2_text_color=&#8221;#FFFFFF&#8221; header_2_font_size=&#8221;32px&#8221; custom_margin=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Programs<\/h2>\n<p>[\/et_pb_text][et_pb_code admin_label=&#8221;Breadcrumbs&#8221; module_class=&#8221;bcrumb&#8221; _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; text_orientation=&#8221;left&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;||||false|false&#8221; custom_css_main_element=&#8221;font-size:16px;||color: #fff;&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Main Content&#8221; _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;2%||2%||true|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;2_3,1_3&#8243; _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;2_3&#8243; _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_post_title meta=&#8221;off&#8221; featured_image=&#8221;off&#8221; admin_label=&#8221;Page Title&#8221; module_class=&#8221;tert-content&#8221; _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_text_color=&#8221;#008c99&#8243; title_font_size=&#8221;39px&#8221; background_enable_image=&#8221;off&#8221; background_size=&#8221;contain&#8221; background_position=&#8221;center_left&#8221; module_alignment=&#8221;left&#8221; custom_margin=&#8221;||0px||false|false&#8221; custom_padding=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_post_title][et_pb_text admin_label=&#8221; Intro Content&#8221; module_class=&#8221;secondary-intro&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; text_font_size=&#8221;24px&#8221; text_line_height=&#8221;1.5em&#8221; header_2_font=&#8221;|600|||||||&#8221; header_2_text_color=&#8221;#008c99&#8243; header_2_font_size=&#8221;39px&#8221; custom_margin=&#8221;||3%||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>The Asthma and Allergy Foundation of America (AAFA), in collaboration with Medlive, offers a variety of free continuing medical education (CME) programs for health care providers. The programs aim to help health care providers learn more about asthma, allergies, atopic diseases, and treatment options. They also provide resources for patient and caregiver support.<\/p>\n<p>[\/et_pb_text][et_pb_text disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Text &#8211; TOC&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>During the programs, expert panelists cover a wide range of topics. For upcoming programs, you can join live or watch on demand later. You can find CME programs on:<\/p>\n<ul>\n<li><a href=\"#asthmatoc\">Asthma<\/a><\/li>\n<li><a href=\"#atopicdermtoc\">Atopic dermatitis (AD) and eczema<\/a><\/li>\n<li><a href=\"#eoetoc\">Eosinophilic esophagitis (EoE)<\/a><\/li>\n<li><a href=\"#foodallergytoc\">Food allergy<\/a><\/li>\n<li><a href=\"#nasalpolypstoc\">Nasal polyps<\/a><\/li>\n<li><a href=\"#type2toc\">Type 2 inflammation<\/a><\/li>\n<li><a href=\"#urticariatoc\">Urticaria<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/secure.aafa.org\/np\/clients\/aafa\/survey.jsp?surveyId=11&amp;\">Sign up for our monthly newsletters<\/a>\u00a0and stay updated on upcoming or on-demand programs.<\/p>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;AME-O Callout&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; background_color=&#8221;#F5EDDF&#8221; custom_padding=&#8221;4%|4%|4%|4%|true|true&#8221; box_shadow_style=&#8221;preset2&#8243; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>AAFA offers asthma management education for nurses and respiratory therapists through our Asthma Management Education Online (AME-O) course. <strong><a href=\"https:\/\/aafa.org\/programs\/education-programs\/asthma-management-education\/\">Learn more about our AME-O course<\/a> <\/strong>and how to earn 9.75 contact hours.<\/p>\n<p>[\/et_pb_text][et_pb_text disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;H3 &#8211; Upcoming Programs &#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; background_color=&#8221;RGBA(255,255,255,0)&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Upcoming programs<\/h2>\n<p>[\/et_pb_text][et_pb_text disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Text &#8211; No Upcoming Programs&#8221; _builder_version=&#8221;4.27.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>There are no upcoming programs at this time. Be sure to check back soon.<\/p>\n<p>[\/et_pb_text][et_pb_text disabled_on=&#8221;on|on|on&#8221; admin_label=&#8221;Text &#8211; Upcoming Programs List&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; disabled=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p><strong>Targeting T2 Inflammation: Taking Action to Efficiently Manage Complex Patients \u2013 A Multidisciplinary Panel Discussion<\/strong><\/p>\n<p><span class=\"NormalTextRun SCXW111082030 BCX0\" data-ccp-charstyle=\"normaltextrun\"><a href=\"https:\/\/www.medlive.com\/hcp\/show\/25-06-12-t2-cme-tether?refCode=PAR_AAFA_CME_T2Tethered_Website_061225\" target=\"_blank\" rel=\"noopener\"><strong>Available on demand starting Thursday, June 12<\/strong><\/a>! Topics include <\/span><span class=\"NormalTextRun SCXW111082030 BCX0\" data-ccp-charstyle=\"normaltextrun\">the exploration of the overlapping nature of type 2 inflammatory conditions, how eosinophilic inflammation impacts disease severity and treatment, and current and emerging biologic therapies that are changing the future of T2 care.<\/span><\/p>\n<p>\u200b<\/p>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;H3 &#8211; PROGRAMS ON ASTHMA AND ALLERGY&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; custom_margin=&#8221;||0px||false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Programs on Asthma and Allergy<\/h2>\n<p>View our programs on asthma and allergy below. <span class=\"TextRun SCXW95978668 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW95978668 BCX0\">Some programs offer<\/span><span class=\"NormalTextRun SCXW95978668 BCX0\"> continuing <\/span><span class=\"NormalTextRun SCXW95978668 BCX0\">medical <\/span><span class=\"NormalTextRun SCXW95978668 BCX0\">educ<\/span><span class=\"NormalTextRun SCXW95978668 BCX0\">ation credits<\/span><span class=\"NormalTextRun SCXW95978668 BCX0\">\u202f<\/span><span class=\"NormalTextRun SCXW95978668 BCX0\">(<\/span><\/span><span class=\"TextRun SCXW95978668 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><em><span class=\"NormalTextRun SCXW95978668 BCX0\">AMA PRA Category 1 Credit\u2122<\/span><\/em><span class=\"NormalTextRun SCXW95978668 BCX0\">)<\/span><\/span><span class=\"TextRun SCXW95978668 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW95978668 BCX0\">, as <\/span><span class=\"NormalTextRun CommentStart CommentHighlightPipeRest CommentHighlightRest SCXW95978668 BCX0\">noted<\/span><span class=\"NormalTextRun CommentHighlightPipeRest SCXW95978668 BCX0\"> below<\/span><span class=\"NormalTextRun SCXW95978668 BCX0\">.<\/span><\/span><\/p>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;H2 &#8211; ASTHMA&#8221; module_id=&#8221;asthmatoc&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Asthma<\/h2>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;Para &#8211; On-demand CME Subhead&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4>\u00a0<\/h4>\n<p><span style=\"color: #008c99\"><strong>On-demand CME<\/strong><\/span><\/p>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;Guideline-driven Management of Moderate and Severe Asthma to Reduce Emergency Care Needs for Exacerbations: A Team-based Initiative&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Guideline-driven Management of Moderate and Severe Asthma (Medlive-Live 05-16-25)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li><span class=\"TextRun SCXW94725435 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW94725435 BCX0\" data-ccp-charstyle=\"normaltextrun\" data-ccp-charstyle-defn=\"{&quot;ObjectId&quot;:&quot;ac0262f4-8a9e-5820-b908-2d943c5f7113|1&quot;,&quot;ClassId&quot;:1073872969,&quot;Properties&quot;:[201342446,&quot;1&quot;,201342447,&quot;5&quot;,201342448,&quot;1&quot;,201342449,&quot;1&quot;,469777841,&quot;Calibri&quot;,469777842,&quot;Arial&quot;,469777843,&quot;Calibri&quot;,469777844,&quot;Calibri&quot;,201341986,&quot;1&quot;,469769226,&quot;Calibri,Arial&quot;,268442635,&quot;22&quot;,469775450,&quot;normaltextrun&quot;,201340122,&quot;1&quot;,134233614,&quot;true&quot;,469778129,&quot;normaltextrun&quot;,335572020,&quot;1&quot;,469778324,&quot;Default Paragraph Font&quot;]}\">Proactive management to reduce <\/span><span class=\"NormalTextRun SCXW94725435 BCX0\" data-ccp-charstyle=\"normaltextrun\">asthma <\/span><span class=\"NormalTextRun SCXW94725435 BCX0\" data-ccp-charstyle=\"normaltextrun\">exacerbations<\/span><span class=\"NormalTextRun SCXW94725435 BCX0\" data-ccp-charstyle=\"scxw158877944\">\u202f<\/span><\/span><\/li>\n<li><span class=\"TextRun SCXW94725435 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW94725435 BCX0\" data-ccp-charstyle=\"normaltextrun\">Case-based learning to improve clinical decision-making and biologic treatment <\/span><span class=\"NormalTextRun SCXW94725435 BCX0\" data-ccp-charstyle=\"normaltextrun\">selection<\/span><span class=\"NormalTextRun SCXW94725435 BCX0\" data-ccp-charstyle=\"scxw158877944\">\u202f<\/span><\/span><\/li>\n<li><span class=\"TextRun SCXW94725435 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW94725435 BCX0\" data-ccp-charstyle=\"normaltextrun\">Best<\/span><span class=\"NormalTextRun SCXW94725435 BCX0\" data-ccp-charstyle=\"normaltextrun\"> practices for ER-to-clinic care transition and patient retention<\/span><span class=\"NormalTextRun SCXW94725435 BCX0\" data-ccp-charstyle=\"scxw158877944\">\u202f<\/span><\/span><span class=\"EOP SCXW94725435 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335559738&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<p>Earn\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 through May 15, 2026. <strong><a href=\"https:\/\/www.medlive.com\/hcp\/show\/25-05-16-asthma-qi-hcp?refCode=PAR_AAFA_CME_AsthmaQI_Website_051625\" target=\"_blank\" rel=\"noopener\">Watch on demand<\/a>.<\/strong><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Inflammation and Beyond: Targeting Airway Remodeling, Hyperresponsiveness, and Mucus Plugging in Moderate to Severe Asthma Through Precision Medicine&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Mucus Plugging in Mod to Severe Asthma (Medlive-Live 01-12-26)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>Assessing\u00a0the\u00a0pathophysiologic changes that lead to airway remodeling<\/li>\n<li>Tailoring\u00a0biologic therapy for individual patients<\/li>\n<li>Delivering\u00a0personalized precision-based asthma care<\/li>\n<\/ul>\n<p>Earn\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 through January 12, 2027. <strong><a href=\"https:\/\/www.medlive.com\/hcp\/show\/26-01-12-asthma-hcp?refCode=par_AAFA_Asthma_011226_website\" target=\"_blank\" rel=\"noopener\">Watch on demand<\/a>.<\/strong><\/p>\n<p>[\/et_pb_toggle][et_pb_text admin_label=&#8221;Para &#8211; On-demand Learning Subhead&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4>\u00a0<\/h4>\n<p><span style=\"color: #008c99\"><strong>On-demand Learning<\/strong><\/span><\/p>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;Applying Guidelines and Latest Evidence to the Management of Moderate\u2010to\u2010Severe Asthma in Children and Adults&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Applying Guidelines &#038; Evidence Management Moderate-to-Severe Asthma (EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]Topics discussed during this program include:<\/p>\n<ul>\n<li>The impact of moderate-to-severe asthma on airway remodeling and lung development in children<\/li>\n<li><span data-contrast=\"none\">Conditions that occur frequently with asthma\u00a0<\/span><\/li>\n<li><span data-contrast=\"none\">Strategies to develop personalized asthma treatment plans\u00a0<\/span><\/li>\n<\/ul>\n<p>Please note\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available.<\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Applying Guidelines and Evidence to the Management of Moderate\u2010to\u2010Severe Asthma\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/tLjEX4sazLU?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/tLjEX4sazLU\" target=\"_blank\" rel=\"noopener\" data-wplink-edit=\"true\">Watch on YouTube<\/a><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Applying the Latest Guidelines and Recommendations to Initiate Biologic Therapy and Control Moderate-to-Severe Asthma Symptoms&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Applying Guidelines-Biologic Therapy &#038; Control Moderate-to-Severe Asthma Symptoms (EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics discussed during this program include:<\/p>\n<ul>\n<li>The burden of uncontrolled asthma<\/li>\n<li>The impact of asthma phenotypes\/endotypes and type 2 comorbidities<\/li>\n<li>Current data on the efficacy and safety of biologics<\/li>\n<\/ul>\n<p>Please note the\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available.<\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Applying the Latest Guidelines to Control Moderate-to-Severe Asthma Symptoms\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/DOHZ0IDD9fs?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/DOHZ0IDD9fs\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Biologic Therapy for Patients with Severe Asthma: Impeding the Inflammatory Cascade&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Biologic Therapy for Patients with Severe Asthma (EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics discussed during this program include:<\/p>\n<ul>\n<li>Roles of various inflammatory pathways in severe asthma<\/li>\n<li>Mechanisms of action of various therapies and their safety and efficacy data<\/li>\n<li>How a new treatment option targeting TSLP can be integrated into asthma management plan<\/li>\n<\/ul>\n<p>Please note <em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available.<\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Biologic Therapy for Patients with Severe Asthma\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/v4tWp8xx6B8?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/v4tWp8xx6B8?si=8jEgp--HGEBQP5M2\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Seeking Control for Moderate-to-Severe Asthma: The Underestimated Impact of Comorbidities Along the Lifespan&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Seeking Control Mod-to-Severe Asthma (3\/5\/24-EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics discussed during this program include:<\/p>\n<ul>\n<li>The effects of comorbid conditions on asthma<\/li>\n<li>The evidence behind biologic treatments for asthma<\/li>\n<li>Strategies to recognize and better manage moderate-to-severe asthma<\/li>\n<\/ul>\n<p>Please note\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available.<\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Seeking Control for Moderate-to-Severe Asthma\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/UQqkQVOd3wI?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;TARGETING ASTHMA: Community-based Strategies to Enhance Care Access for Children, Adolescents, and Adults \u2013 Focus on Social Determinants of Health and Inequities of Care&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; TARGETING ASTHMA: SDOH and Inequities of Care (EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics discussed during this program include:<\/p>\n<ul>\n<li>Strategies to enhance access to individualized care among people of racial and ethnic minorities<\/li>\n<li>How to identify patients with moderate-to-severe asthma who may benefit from targeted biologic agents<\/li>\n<li>How to identify the place of type-2-targeted biologics in the management of moderate-to-severe asthma<\/li>\n<\/ul>\n<p>Please note <em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available.<\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Targeting Asthma and Strategies to Enhance Care Access\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/Gdl-9T7-CVU?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/Gdl-9T7-CVU?si=c6WOToN38qoyUORB\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p>[\/et_pb_toggle][et_pb_text admin_label=&#8221;H2 &#8211; FOOD ALLERGY&#8221; module_id=&#8221;foodallergytoc&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;10px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>&nbsp;<\/p>\n<h2>Food Allergy<\/h2>\n<p>[\/et_pb_text][et_pb_text disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Para &#8211; On-demand CME Subhead&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4>\u00a0<\/h4>\n<p><span style=\"color: #008c99\"><strong>On-demand CME<\/strong><\/span><\/p>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;The Growing Role of PCPs and Pediatricians in the Management of IgE-mediated Food Allergies&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Growing Role PCPs Peds Management Food Allergies (12\/4\/25-LIVE)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>Where new biologics and epinephrine nasal spray fit in food allergy care<\/li>\n<li>Current guidelines for managing IgE-mediated food allergy and anaphylaxis<\/li>\n<li>Applying shared decision-making to guide treatment choices and improve safety<\/li>\n<\/ul>\n<p>Earn\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 through December 4, 2026. <strong><a href=\"https:\/\/www.medlive.com\/patient\/show\/25-12-04-the-growing-role-of-?refCode=par_AAFA_120425_IgE-mediated_Food_Allergies_OD_website\" target=\"_blank\" rel=\"noopener\">Watch on demand<\/a>.<\/strong><\/p>\n<p>[\/et_pb_toggle][et_pb_text admin_label=&#8221;Para &#8211; On-demand Learning Subhead&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4>\u00a0<\/h4>\n<p><span style=\"color: #008c99\"><strong>On-demand Learning<\/strong><\/span><\/p>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;At the Forefront of Food Allergies: Preventive Strategies to Improve Outcomes&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; At the Forefront of Food Allergies: Preventive Strategies to Improve Outcomes (EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics discussed during this program include:<\/p>\n<ul>\n<li>The changing landscape of food allergy management<\/li>\n<li><span data-contrast=\"none\">Newer approaches to enhance food allergen tolerance<\/span><\/li>\n<li><span data-contrast=\"none\">The key roles of patients and their families when making therapeutic decisions\u00a0<\/span><\/li>\n<\/ul>\n<p>Please note\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available. There are two sessions in this program.<\/p>\n<p><strong>Session 1<\/strong><\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Management of Food Allergies \u2013 Prevention of Allergic and Anaphylactic Reactions\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/phL-YwUv92k?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/phL-YwUv92k\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p><strong>Session 2<\/strong><\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: IgE-Therapies in Team-based Management of Food Allergies\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/NExGuUbbod8?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/NExGuUbbod8\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;IgE-targeted Therapies and the Future Management of Food Allergies&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; IgE Targeted Therapies-Future Mgmt Food Allergies (3\/24-EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics discussed during this program include:<\/p>\n<ul>\n<li>The diagnostic process for food allergies<\/li>\n<li><span data-contrast=\"none\">Emerging biologics targeting IgE<\/span><\/li>\n<li><span data-contrast=\"none\">The role of shared decision-making in food allergy management<\/span><\/li>\n<\/ul>\n<p>Please note\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available.<\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: IgE-targeted Therapies and the Future Management of Food Allergies\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/tdDZqx4ex6k?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p>[\/et_pb_toggle][et_pb_text admin_label=&#8221;H3 &#8211; PROGRAMS ON ALLERGIC CONDITIONS&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; custom_margin=&#8221;||0px||false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>\u00a0<\/h3>\n<h3>Programs on Allergic Conditions<\/h3>\n<p>View our programs on allergic conditions such as chronic spontaneous urticaria (CSU), eosinophilic esophagitis (EoE), atopic dermatitis (AD), and more. You can earn an <em>AMA PRA Category 1 Credit<\/em>\u2122, as noted.<\/p>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;H2 &#8211; ATOPIC DERMATITIS&#8221; module_id=&#8221;atopicdermtoc&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>Atopic Dermatitis<\/h2>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;Para &#8211; On-demand CME Subhead&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4>\u00a0<\/h4>\n<p><span style=\"color: #008c99\"><strong>On-demand CME<\/strong><\/span><\/p>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;Caring for the Littles with Atopic Dermatitis: Clinician-Caregiver Collaboration&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;on|on|on&#8221; admin_label=&#8221;Toggle &#8211; Caring for Littles AD-Clinician-Caregiver Collaboration (8\/21\/24-EXPIRED NEED VID)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; disabled=&#8221;on&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>Guideline recommendations for the management of moderate-to-severe atopic dermatitis (AD) in infants and young children<\/li>\n<li>Efficacy and safety data from recent studies on treatments<\/li>\n<li>The effects of newer treatments for AD on patient outcomes<\/li>\n<\/ul>\n<p>Earn\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 through August 21, 2025. <strong><a href=\"https:\/\/www.medlive.com\/hcp\/show\/24-08-21-pediatric-atopic-der\/isovx-presentation-page?RefCode=PAR_AAFA_CME_PediatricAtopicDerm_Website_082124\" target=\"_blank\" rel=\"noopener\">Watch on demand<\/a>.<\/strong><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/www.medlive.com\/hcp\/show\/24-08-21-pediatric-atopic-der\/isovx-presentation-page?RefCode=PAR_AAFA_CME_PediatricAtopicDerm_Website_082124\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-22243\" src=\"https:\/\/aafa.org\/wp-content\/uploads\/2024\/11\/AAFA-Thumbnail-Caring-For-Littles-AtopicDerm-Medlive-CME-Program-240821.jpg\" alt=\"Caring for the Little with Atopic Dermatitis: Clinical-Caregiver Collaboration\" width=\"600\" height=\"333\" srcset=\"https:\/\/aafa.org\/wp-content\/uploads\/2024\/11\/AAFA-Thumbnail-Caring-For-Littles-AtopicDerm-Medlive-CME-Program-240821.jpg 600w, https:\/\/aafa.org\/wp-content\/uploads\/2024\/11\/AAFA-Thumbnail-Caring-For-Littles-AtopicDerm-Medlive-CME-Program-240821-480x267.jpg 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) 600px, 100vw\" \/><\/a><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Atopic Dermatitis in Focus: Strategies for Sustained Flare Control in Chronic Disease&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; AD Derm Focus: Strategies Sustained Flare Control (8\/11\/26-LIVE)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>How long-term management of atopic dermatitis is essential for improving outcomes<\/li>\n<li>The use of advanced therapies to manage atopic dermatitis<\/li>\n<li>How to improve treatment adherence and long-term outcomes<\/li>\n<\/ul>\n<p>Earn\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 through August 11, 2027. <strong><a href=\"https:\/\/www.medlive.com\/hcp\/show\/26-08-11-atopic-derm-ml-tethe?refcode=6RJ68E9H7JZH0_AAFAwebsite_OnSiteProduct\" target=\"_blank\" rel=\"noopener\">Watch on demand<\/a>.<\/strong><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Moderate-to-Severe Atopic Dermatitis in Primary Care: Recognizing, Treating, and Knowing When to Escalate Across the Lifespan &#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; AD Primary Care: Across the Lifespan (7\/15\/26-LIVE)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>Recognizing how atopic dermatitis presents from infancy through older adulthood<\/li>\n<li>Identifying when to escalate care or refer to a specialist<\/li>\n<li>Coordinating care for patients receiving specialist-direct therapies<\/li>\n<\/ul>\n<p>Earn\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 through July 15, 2027. <a href=\"https:\/\/www.medlive.com\/aafpcme\/show\/26-07-15-atopic-dermatitis-li?refCode=TL952BKD5PZVR_AAFAWebsite_OnSiteProduct\" target=\"_blank\" rel=\"noopener\"><strong>Watch on demand.<\/strong><\/a><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Uncovering the Spectrum of Comorbidities in Moderate-to-Severe Atopic Dermatitis: How to Navigate the Nuances to Comprehensive Care&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Uncovering Spectrum Comorbidities Exchange AD (10\/9\/25-LIVE)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>Comorbid conditions\u202fcommon with atopic dermatitis (AD)<\/li>\n<li>The impact of comorbid conditions on AD management<\/li>\n<li>Strategies to improve overall treatment and quality of life<\/li>\n<\/ul>\n<p>Earn\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 through October 6, 2026. <strong><a href=\"https:\/\/www.medlive.com\/hcp\/show\/25-10-08-atopic-dermatits-hcp?refCode=PAR_AAFA_CME_AtopicDerm_Website_100925\" target=\"_blank\" rel=\"noopener\">Watch on demand<\/a>.<\/strong><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Rapid Relief of Difficult-to-Treat Hand and Foot Atopic Dermatitis&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;on|on|on&#8221; admin_label=&#8221;Toggle &#8211; Rapid Relief Hand &#038; Foot AD (10\/18\/24-EXPIRED NEED VID)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; disabled=&#8221;on&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>Practical tips on assessing disease severity<\/li>\n<li>Treatment strategies and managing side effects<\/li>\n<li>Challenging case studies of hand and foot atopic dermatitis<\/li>\n<li>Efficacy and safety data from recent studies on treatments<\/li>\n<li>The effects of newer treatments for AD on patient outcomes<\/li>\n<\/ul>\n<p>Earn\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 through October 18, 2025. <strong><a href=\"https:\/\/medlive.com\/hcp\/show\/24-10-18-hand-and-foot-atopic?RefCode=PAR_AAFA_CME_HafAtopic_Web_101824\" target=\"_blank\" rel=\"noopener\">Watch on demand<\/a>.<\/strong><\/p>\n<p>[\/et_pb_toggle][et_pb_text admin_label=&#8221;Para &#8211; On-demand Learning Subhead&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4>\u00a0<\/h4>\n<p><span style=\"color: #008c99\"><strong>On-demand Learning<\/strong><\/span><\/p>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;Atopic Dermatitis and Its Comorbid Conditions: How Knowing About Them Will Help Guide Your Treatment Decisions&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Atopic Dermatitis and Its Comorbid Conditions (EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>Current evidence for currently approved agents for the treatment of moderate-to-severe atopic dermatitis (AD)<\/li>\n<li>How the presence of comorbidities can influence the treatment of moderate-to-severe AD<\/li>\n<li>How to help patients reach long-term control of their disease<\/li>\n<\/ul>\n<p>Please note\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available.<\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Atopic Dermatitis and Its Comorbid Conditions\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/hVWjUvMG8nQ?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/hVWjUvMG8nQ\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Disparity and Equity in Moderate-to-Severe AD Care: Enhancing Access to Multidisciplinary Care for Patients from Diverse Populations&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Disparity and Equity in Moderate-to-Severe AD Care (EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>The impacts that age, race, and ethnicity have on atopic dermatitis (AD)<\/li>\n<li>Management of moderate-to-severe\u00a0atopic dermatitis<\/li>\n<li>The unique challenges that people from diverse racial and ethnic group face when attempting to access care<\/li>\n<\/ul>\n<p>Please note <em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available.<\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Disparity and Equity in Moderate-to-Severe AD Care\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/kTuU9T3zk6U?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/kTuU9T3zk6U?si=I7sILIQ0j7ZONu9k\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Endophenotypes, Evidence, and Long-Term Outcomes in Moderate-to-Severe Atopic Dermatitis Management: A Decision Library&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Endophenotypes, Evidence Moderate-to-Severe AD (EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>Alignment of therapeutic decisions to clinical endophenotypes in patients of different age groups and races<\/li>\n<li>Evidence-based treatment recommendations to achieve long-term disease control<\/li>\n<li>Strategies to encourage shared-decision-making with patients<\/li>\n<\/ul>\n<p>Please note <em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available. There are four modules in this program.<\/p>\n<p><strong>Module 1<\/strong><\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Atopic Dermatitis Endophenotypes \u2013 Implications for Management\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/_EIVCyec8gg?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/_EIVCyec8gg?si=SSTMHprP_G2iT4j4\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p><strong>Module 2 <\/strong><\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Treatment of Moderate-to-Severe Atopic Dermatitis\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/u_a-ma7sRXc?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/u_a-ma7sRXc?si=clq0umnmHBPb9ofI\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p><strong>Module 3<\/strong><\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Long-Term Maintenance in Atopic Dermatitis\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/rKzld70uDkU?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/rKzld70uDkU?si=25FvDtBlXQdiTE1f\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p><strong>Module 4<\/strong><\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Accessing Care and Setting and Maintaining Atopic Dermatitis Goals\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/ABMYZEZxKhI?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/ABMYZEZxKhI?si=kb2Ih-V_ahwGsubY\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p>[\/et_pb_toggle][et_pb_text admin_label=&#8221;H2 &#8211; EOSINOPHILIC ESOPHAGITIS&#8221; module_id=&#8221;eoetoc&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;10px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>&nbsp;<\/p>\n<h2>Eosinophilic Esophagitis<\/h2>\n<p>[\/et_pb_text][et_pb_text disabled_on=&#8221;on|on|on&#8221; admin_label=&#8221;Para &#8211; On-demand CME Subhead&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; disabled=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4>\u00a0<\/h4>\n<p><span style=\"color: #008c99\"><strong>On-demand CME<\/strong><\/span><\/p>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;Type 2 Inflammation in the Gut: Implications for Treatment of EoE and Other Eosinophilic Gastrointestinal Diseases&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;on|on|on&#8221; admin_label=&#8221;Toggle &#8211; EoE &#038; EGID: Type 2 Inflammation in the Gut (12\/21\/24-EXPIRED NEED VID)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; disabled=&#8221;on&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>The underlying pathophysiology of EoE and non-EoE eosinophilic gastrointestinal diseases (EGIDS)<\/li>\n<li>Safety and efficacy data with current and emerging therapies of EoE<\/li>\n<li>The current evidence on the efficacy and safety data of emerging biologics for non-EoE EGIDs<\/li>\n<\/ul>\n<p>Earn\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 through Dec. 12, 2025. <strong><a href=\"https:\/\/medlive.com\/hcp\/show\/24-12-12-eoe-eid-cme-session?RefCode=PAR_AAFA_CME_EoEEGID_Website_121224\" target=\"_blank\" rel=\"noopener\">Watch on demand<\/a>.<\/strong><\/p>\n<p>[\/et_pb_toggle][et_pb_text admin_label=&#8221;Para &#8211; On-demand Learning Subhead&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4>\u00a0<\/h4>\n<p><span style=\"color: #008c99\"><strong>On-demand Learning<\/strong><\/span><\/p>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;Enhancing Diagnosis and Access to Treatment in EoE: What You Need to Know from Your Patients&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; EoE Diagnosis &#038; Treatment: Know From Your Patients  (EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics discussed during this program include:<\/p>\n<ul>\n<li>Guidance on EoE diagnosis<\/li>\n<li>The Importance of asking questions to uncover adaptive behaviors<\/li>\n<li>Details of the current treatment paradigm<\/li>\n<\/ul>\n<p>Please note\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available.<\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Enhancing Diagnosis and Access to Treatment in Eosinophilic Esophagitis (EoE)\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/jRynsP4nipY?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/jRynsP4nipY\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;EoE in the Littles: Early Diagnosis and New Treatment Options&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; EoE in the Littles: Early Diagnosis and New Treatment Options (11\/21\/24-EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>The symptoms of eosinophilic esophagitis (EoE) in babies and young children<\/li>\n<li>Safety and efficacy data from clinical trials of newly approved agents for EoE in babies and young children<\/li>\n<li>Strategies to counsel children with EoE and their caregivers on best practices for care transitions as children reach adolescence and adulthood<\/li>\n<\/ul>\n<p>Please note\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available.<\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: EoE in the Littles: Early Diagnosis and New Treatment Options\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/TsrZcNsKK0o?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/TsrZcNsKK0o\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Eosinophilic Esophagitis: Guidelines and Emerging Evidence for Effective Management Strategies&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; EoE Guidelines and Emerging Evidence (EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics discussed during this program include:<\/p>\n<ul>\n<li>How to recognize the symptoms of eosinophilic esophagitis (EoE) across a variety of patient ages to facilitate an early diagnosis<\/li>\n<li>Emerging data on new, more efficient, targeted agents for the management of EoE<\/li>\n<\/ul>\n<p>Please note <em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available.<\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Management Strategies for Eosinophilic Esophagitis (EoE)\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/aNBg9VpstiA?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/aNBg9VpstiA?si=xF6E-dnzSQvbQcQP\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p>[\/et_pb_toggle][et_pb_text admin_label=&#8221;H2 &#8211; NASAL POLYPS&#8221; module_id=&#8221;nasalpolypstoc&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;10px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>&nbsp;<\/p>\n<h2>Nasal Polyps<\/h2>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;Para &#8211; On-demand CME Subhead&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4>\u00a0<\/h4>\n<p><span style=\"color: #008c99\"><strong>On-demand CME<\/strong><\/span><\/p>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;Smell Matters: Breakthrough Strategies to Restore Olfaction in CRSwNP&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Smell Matters Restoring Olfaction in CRSwNP (11\/25-LIVE)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li><span data-contrast=\"auto\">Strategies to restore sense of smell<\/span><\/li>\n<li><span data-contrast=\"auto\">When and how to use biologic therapies to treat chronic rhinosinusitis with nasal polyps (CRSwNP)<\/span><\/li>\n<li>How to personalize treatment plans to improve patient outcomes<span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<p>Earn\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 through Nov. 17, 2026. <strong><a href=\"https:\/\/www.medlive.com\/hcp\/show\/25-11-17-nasal-polyps-hcp?refCode=par_AAFA_111725_Nasal_Polyps_HCP_OD_website\" target=\"_blank\" rel=\"noopener\">Watch on demand<\/a>.<\/strong><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Expert Interview and Short Modules Series: Emerging Topics in Nasal Polyps Management&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;on|on|on&#8221; admin_label=&#8221;Toggle &#8211; Expert Interview\/Short Modules Series: Emerging Topics in NP Mgmt (8\/22\/24-EXPIRED NEED VID)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; disabled=&#8221;on&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>Strategies to improve olfactory dysfunction in chronic rhinosinusitis with nasal polyps (CRSwNP)<\/li>\n<li>Applying evidence-based guidelines on CRSwNP and managing comorbidities to treat the patient as a whole<\/li>\n<li>Long-term efficacy data for biologic therapy from real-world studies in the treatment of nasal polyps<\/li>\n<\/ul>\n<p>Earn\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 through August 25, 2025. <strong><a href=\"https:\/\/www.medlive.com\/hcp\/show\/24-08-22-nasal-polyps-modular\/qziia-presentation-page?RefCode=PAR_AAFA_CME_NasalPolypsMI_Website_082224\" target=\"_blank\" rel=\"noopener\">Watch on demand<\/a>.<\/strong><\/p>\n<p><a href=\"https:\/\/www.medlive.com\/hcp\/show\/24-08-22-nasal-polyps-modular\/qziia-presentation-page?RefCode=PAR_AAFA_CME_NasalPolypsMI_Website_082224\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-22240\" src=\"https:\/\/aafa.org\/wp-content\/uploads\/2024\/11\/AAFA-Thumbnail-NasalPolyps-Expert-Interview-Medlive-CME-Program-240822.jpg\" alt=\"Expert Interview and Short Modules Series: Emerging Topics in Nasal Polyps Management\" width=\"600\" height=\"333\" srcset=\"https:\/\/aafa.org\/wp-content\/uploads\/2024\/11\/AAFA-Thumbnail-NasalPolyps-Expert-Interview-Medlive-CME-Program-240822.jpg 600w, https:\/\/aafa.org\/wp-content\/uploads\/2024\/11\/AAFA-Thumbnail-NasalPolyps-Expert-Interview-Medlive-CME-Program-240822-480x267.jpg 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) 600px, 100vw\" \/><\/a><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Applying Nasal Polyps Guidelines to Cases: How Do Your Treatment Decisions Compare with the Experts?&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;on|on|on&#8221; admin_label=&#8221;Toggle &#8211; Applying Nasal Polyps Guidelines to Cases (12\/20\/24-EXPIRED NEED VID)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; disabled=&#8221;on&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>The impact of chronic rhinosinusitis with nasal polyps (CRSwNP) on comorbidity outcomes<\/li>\n<li>Case studies of challenging CRSwNP diagnoses<\/li>\n<li>Guideline recommendations for CRSwNP treatment options<\/li>\n<\/ul>\n<p>Earn\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 through Dec. 20, 2025. <strong><a href=\"https:\/\/medlive.com\/hcp\/show\/24-11-12-np-guideline-summit?refCode=PAR_AAFA_CME_NasalPolyps_Website_122024\" target=\"_blank\" rel=\"noopener\">Watch on demand<\/a>.<\/strong><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Improving Sense of Smell in Chronic Rhinosinusitis with Nasal Polyposis: A Tethered Curriculum&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;on|on|on&#8221; admin_label=&#8221;Toggle &#8211; Improving Sense of Smell Nasal Polyps (11\/20\/24-EXPIRED NEED VID)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; disabled=&#8221;on&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>The mechanism behind olfactory dysfunction in patients with chronic rhinosinusitis with nasal polyps (CRSwNP)<\/li>\n<li>Tools and strategies to evaluate olfactory function in patients with CRSwNP<\/li>\n<li>The burden of CRSwNP on patients<\/li>\n<\/ul>\n<p>Earn\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 through Nov. 20, 2025. <strong><a href=\"https:\/\/medlive.com\/hcp\/show\/24-09-06-nasal-polyps-tether-?RefCode=PAR_AAFA_CME_NasalPolyps_Website_112024\" target=\"_blank\" rel=\"noopener\">Watch on demand<\/a>.<\/strong><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Where Do Biologic Therapies Fit in Guideline-Concordant Care for Nasal Polyps?&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;on|on|on&#8221; admin_label=&#8221;Toggle &#8211; Where Do Biologic Therapies Fit in Guideline-Concordant Care for Nasal Polyps? (11\/12\/24-EXPIRED NEED VID)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; disabled=&#8221;on&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>The criteria for the candidacy of biologic therapy for chronic rhinosinusitis with nasal polyps (CRSwNP) in the EPOS\/EUFOREA guidelines<\/li>\n<li>The place of biologic therapy in current treatment guidelines<\/li>\n<li>The relative impact of various treatment in improving olfaction and other patient-valued parameters.<\/li>\n<\/ul>\n<p>Earn\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 through Nov. 12, 2025. <strong><a href=\"https:\/\/medlive.com\/hcp\/show\/24-11-12-np-guideline-summit ?RefCode=PAR_AAFA_CME_NasalPolyps_Website_112024\" target=\"_blank\" rel=\"noopener\" data-wplink-url-error=\"true\">Watch on demand<\/a>.<\/strong><\/p>\n<p>[\/et_pb_toggle][et_pb_text admin_label=&#8221;Para &#8211; On-demand Learning Subhead&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4>\u00a0<\/h4>\n<p><span style=\"color: #008c99\"><strong>On-demand Learning<\/strong><\/span><\/p>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;Caring for Patients with Nasal Polyps in 2023: When to Consider a Biologic or Surgery?&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Caring for Patients w\/NP-Biologic or Surgery 2023 (EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>The latest understanding of chronic rhinosinusitis with nasal polyps (CRSwNP), or nasal polyps<\/li>\n<li>People at high risk for recurrence of nasal polyps<\/li>\n<li>Treatment options for people with nasal polyps<\/li>\n<\/ul>\n<p>Please note\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available. There are four modules in this program.<\/p>\n<p><strong>Module 1<\/strong><\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Key Symptoms of Nasal Polyps &amp; Their Impact on Quality of Life\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/zwYBtX3mUkw?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/zwYBtX3mUkw\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p><strong>Module 2<\/strong><\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: CRSwNP and Its Comorbidities \u2013 Burden on Patients\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/cJu14uu3QGg?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/cJu14uu3QGg\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p><strong>Module 3<\/strong><\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Inflammatory Pathways Involved in Nasal Polyps Formation\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/6eIQ4OGS7jI?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/6eIQ4OGS7jI\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p><strong>Module 4<\/strong><\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Treatment Pathways for Nasal Polyps\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/A2voV_D0hhI?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/A2voV_D0hhI\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Cases in Practice: Applying Proposed Care Pathways for Interdisciplinary Collaboration to the Management of Nasal Polyps&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Cases in Practice: Management of Nasal Polyps (EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"22\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">Cases illustrating the adoption of biologics as a therapeutic option for nasal polyps\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"22\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"2\" data-aria-level=\"1\"><span data-contrast=\"auto\">The underlying pathophysiology of nasal polyps driven by type 2 inflammation<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"22\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"3\" data-aria-level=\"1\"><span data-contrast=\"auto\">Strategies for implementing interdisciplinary collaborative care<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<p>Please note\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available.<\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Applying Proposed Care Pathways to the Management of Nasal Polyps\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/VSVqRd6xOg4?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/VSVqRd6xOg4\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Diagnostic Workup of the Patient with Uncontrolled Severe Nasal Polyps: Proposed Pathway to Determine Candidacy for Biologic Therapy&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Diagnostic Workup Patient with Uncontrolled Severe NP (EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>Patient factors to predict relapse risk and determine candidacy for biologics<\/li>\n<li>Emerging models for interdisciplinary collaboration in the care of people with nasal polyps<\/li>\n<\/ul>\n<p>Please note\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available.<\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Diagnostic Workup of the Patient with Uncontrolled Severe Nasal Polyps\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/qYOUzIESIPc?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/qYOUzIESIPc\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Moving Toward a Targeted Approach for Nasal Polyps&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Targeted Approach for Nasal Polyps (EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics discussed during this course include:<\/p>\n<ul>\n<li>The patient burden of nasal polyps<\/li>\n<li>Limitations of traditional nasal polyp treatments and emerging therapies for those with nasal polyps<\/li>\n<li>Rationale for targeted approaches to nasal polyp management<\/li>\n<\/ul>\n<p>Please note <em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available.<\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Targeted Therapies for Nasal Polyps\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/UJAEWCkatZM?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/UJAEWCkatZM?si=SAoLsWNRof_3pEZy\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Multidisciplinary Approach to the Management of CRS with Refractory Nasal Polyps: ENT, Allergist, and Patient Partnerships to Enhance Care and QoL &#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Multidisciplinary Approach &#8211; Refractory Nasal Polyps (EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; hover_enabled=&#8221;0&#8243; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p>Topics discussed during this program include:<\/p>\n<ul>\n<li>Patient-centered treatment options for chronic rhinosinusitis with nasal polyps (CRSwNP)<\/li>\n<li>Disease burden<\/li>\n<li>The impacts that biologics and surgery have on symptoms and quality of life (QoL)<\/li>\n<\/ul>\n<p>Please note <em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available.<\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Multidisciplinary Approach to the Management of CRS with Refractory Nasal Polyps\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/SrwI1QMQ7x4?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/SrwI1QMQ7x4?si=RtpCHIKaE0DCsAaf\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Surgery or Biologic for Nasal Polyps? A Close Look at the Evidence&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Surgery or Biologic for Nasal Polyps? (EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics discussed during this program include:<\/p>\n<ul>\n<li>The underlying pathways that lead to nasal polyps and drive recurrent disease and treatment resistance<\/li>\n<li>The burdens faced by patients with nasal polyps<\/li>\n<li>Evidence supporting the efficacy and safety of biologic agents for the treatment of nasal polyps<\/li>\n<\/ul>\n<p>Please note\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available.<\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Surgery or Biologic for Nasal Polyps? A Look at the Evidence\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/4dyLAGMpmNw?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/4dyLAGMpmNw\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_toggle][et_pb_text admin_label=&#8221;H2 &#8211; TYPE 2 INFLAMMATION&#8221; module_id=&#8221;type2toc&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>&nbsp;<\/p>\n<h2>Type 2 Inflammation<\/h2>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;Para &#8211; On-demand CME Subhead&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4>\u00a0<\/h4>\n<p><span style=\"color: #008c99\"><strong>On-demand CME<\/strong><\/span><\/p>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;Multidisciplinary Management of T2 Inflammatory Diseases: Case-based Discussion&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Multidisciplinary Management of T2 (8\/20\/25-LIVE)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>The impact of coexisting type 2 inflammatory diseases on severity and treatment<\/li>\n<li>Strategies to implement multidisciplinary management models<\/li>\n<li>Data evaluation for targeted biologics<\/li>\n<\/ul>\n<p>Earn\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 through August 20, 2026. <strong><a href=\"https:\/\/www.medlive.com\/hcp\/show\/25-08-20-multidisciplinary-ma?refCode=PAR_AAFA_CME_T2Tethered_Website_082025\" target=\"_blank\" rel=\"noopener\">Watch on demand<\/a>.<\/strong><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Targeting T2 Inflammation: Taking Action to Efficiently Manage Complex Patients \u2013 A Multidisciplinary Panel Discussion&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Targeting T2 Inflammation: Taking Action  (6\/12\/25-LIVE)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>The exploration of the overlapping nature of type 2 inflammatory conditions like asthma, atopic dermatitis, EoE, and CRSwNP<\/li>\n<li>How eosinophilic inflammation impacts disease severity and treatment<\/li>\n<li>Current and emerging biologic therapies that are changing the future of T2 care<\/li>\n<\/ul>\n<p>Earn\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 through June 12, 2026. <strong><a href=\"https:\/\/www.medlive.com\/hcp\/show\/25-06-12-t2-cme-tether?refCode=PAR_AAFA_CME_T2Tethered_Website_061225\" target=\"_blank\" rel=\"noopener\">Watch on demand<\/a>.<\/strong><\/p>\n<p>[\/et_pb_toggle][et_pb_text admin_label=&#8221;H2 &#8211; URTICARIA&#8221; module_id=&#8221;urticariatoc&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;10px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>&nbsp;<\/p>\n<h2>Urticaria<\/h2>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;Para &#8211; On-demand CME Subhead&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4>\u00a0<\/h4>\n<p><span style=\"color: #008c99\"><strong>On-demand CME<\/strong><\/span><\/p>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;\u201cHive Hopes\u201d for Chronic Spontaneous Urticaria: Targeting Key Immune Pathways with the Latest Emerging Therapies&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Hive Hopes for CSU (7\/28\/25-LIVE)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics covered during this program include:<\/p>\n<ul>\n<li>Updated international guidelines and key diagnostic tools<\/li>\n<li>The role of inflammatory pathways<\/li>\n<li>How delays in diagnosis can leave patients without relief<\/li>\n<\/ul>\n<p>Earn\u00a0<em>AMA PRA Category 1 Credit<\/em>\u2122 through July 28, 2026. <strong><a href=\"https:\/\/www.medlive.com\/hcp\/show\/25-07-28-csu?refCode=PAR_AAFA_CME_CSU_Website_072825\" target=\"_blank\" rel=\"noopener\">Watch on demand<\/a>.<\/strong><\/p>\n<p>[\/et_pb_toggle][et_pb_text admin_label=&#8221;Para &#8211; On-demand Learning Subhead&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; header_text_color=&#8221;#505050&#8243; header_2_text_color=&#8221;#505050&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4>\u00a0<\/h4>\n<p><span style=\"color: #008c99\"><strong>On-demand Learning<\/strong><\/span><\/p>\n<p>[\/et_pb_text][et_pb_toggle title=&#8221;The Increasing Importance of Identifying Urticaria Subtypes to Achieve Control: Opportunities with T2 Inflammation Targeting Agents&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; Identifying Urticaria Subtypes to Achieve Control (EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics discussed during this program include:<\/p>\n<ul>\n<li>The relationships between chronic inducible urticaria (CIndU) triggers and underlying pathophysiologic pathways<\/li>\n<li>How to optimize treatment of chronic spontaneous urticaria (CSU) and CIndU<\/li>\n<li>Strategies to identify urticaria subtypes<\/li>\n<\/ul>\n<p>Please note <em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available.<\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: The Importance of Identifying Urticaria Subtypes to Achieve\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/hOThcuKnE5M?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/hOThcuKnE5M?si=NH35iD1L3RV7YItU\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p>[\/et_pb_toggle][et_pb_toggle title=&#8221;Chronic Spontaneous Urticaria: New Hope with Emerging Targeted Agents&#8221; open_toggle_text_color=&#8221;#FFFFFF&#8221; open_toggle_background_color=&#8221;#f0f0f0&#8243; closed_toggle_text_color=&#8221;#FFFFFF&#8221; closed_toggle_background_color=&#8221;#f0f0f0&#8243; icon_color=&#8221;#FFFFFF&#8221; toggle_icon=&#8221;&#x4c;||divi||400&#8243; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;20px&#8221; open_icon_color=&#8221;#FFFFFF&#8221; open_toggle_icon=&#8221;&#x4b;||divi||400&#8243; open_use_icon_font_size=&#8221;on&#8221; open_icon_font_size=&#8221;20px&#8221; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Toggle &#8211; CSU: New Hope with Emerging Targeted Agents (EXPIRED)&#8221; module_class=&#8221;accord&#8221; _builder_version=&#8221;4.27.6&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#FFFFFF&#8221; title_font=&#8221;|600|||||||&#8221; title_text_align=&#8221;left&#8221; title_font_size=&#8221;22px&#8221; closed_title_font=&#8221;|600|||||||&#8221; closed_title_text_align=&#8221;left&#8221; closed_title_font_size=&#8221;22px&#8221; closed_title_line_height=&#8221;1em&#8221; body_text_color=&#8221;#505050&#8243; body_font_size=&#8221;16px&#8221; text_orientation=&#8221;left&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;&#8221; width_last_edited=&#8221;on|phone&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|tablet&#8221; height=&#8221;333&#8243; custom_margin=&#8221;||2%||false|false&#8221; custom_padding=&#8221;0px|0px|0px|0px|true|true&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>Topics discussed during this program include:<\/p>\n<ul>\n<li>The latest in chronic spontaneous urticaria (CSU) treatment options<\/li>\n<li>Management and treatment escalation standards<\/li>\n<li>Perspectives from the patient journey<\/li>\n<\/ul>\n<p>Please note <em>AMA PRA Category 1 Credit<\/em>\u2122 is no longer available.<\/p>\n<p><iframe loading=\"lazy\" title=\"Webinar: Treating Chronic Spontaneous Urticaria\" width=\"1080\" height=\"608\" src=\"https:\/\/www.youtube.com\/embed\/5jEma9VJq5o?feature=oembed\"  allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/youtu.be\/5jEma9VJq5o?si=uJAfgv3PMuL5TKx0\" target=\"_blank\" rel=\"noopener\">Watch on YouTube<\/a><\/p>\n<p>[\/et_pb_toggle][et_pb_code admin_label=&#8221;Print&#8221; module_id=&#8221;print&#8221; module_class=&#8221;clearfix&#8221; _builder_version=&#8221;4.17.6&#8243; _module_preset=&#8221;default&#8221; global_module=&#8221;5156&#8243; saved_tabs=&#8221;all&#8221; global_colors_info=&#8221;{}&#8221;]<a href=\"https:\/\/aafa.org\/programs\/education-programs\/asthma-allergies-continuing-education-cme\/print\/\" rel=\"nofollow\" title=\"Print post\"><svg class=\"WP-PrintIcon wp-print-icon\" width=\"16\" height=\"16\" viewbox=\"0 0 20 20\" fill=\"currentColor\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M6 2h8v4H6z\" \/><path d=\"M3 7h14v7h-3v-3H6v3H3z\" \/><path d=\"M6 12h8v6H6z\" \/><\/svg> Print post<\/a> [\/et_pb_code][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;6%||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/aafa.org\/wp-content\/uploads\/2022\/11\/breathe-subscribe-ad.png&#8221; title_text=&#8221;breathe-subscribe-ad&#8221; url=&#8221;https:\/\/secure.aafa.org\/np\/clients\/aafa\/survey.jsp?surveyId=11&#038;&#8221; url_new_window=&#8221;on&#8221; force_fullwidth=&#8221;on&#8221; admin_label=&#8221;Breathe eNewsletter Subsciption Button&#8221; _builder_version=&#8221;4.22.2&#8243; _module_preset=&#8221;default&#8221; global_module=&#8221;8218&#8243; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_button button_url=&#8221;\/asthma-allergy-education-programs\/&#8221; url_new_window=&#8221;on&#8221; button_text=&#8221;EDUCATION PROGRAMS&#8221; button_alignment=&#8221;center&#8221; admin_label=&#8221;Education Programs Button&#8221; _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; custom_button=&#8221;on&#8221; button_bg_color=&#8221;#28BDBA&#8221; button_font=&#8221;|600|||||||&#8221; button_use_icon=&#8221;off&#8221; custom_css_main_element=&#8221;width:100%;&#8221; global_module=&#8221;8561&#8243; saved_tabs=&#8221;all&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][et_pb_text admin_label=&#8221;Support Our Work Blurb&#8221; module_class=&#8221;sidebar-blurb&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; text_font_size=&#8221;16px&#8221; text_line_height=&#8221;1.5em&#8221; link_font=&#8221;|600||on|||||&#8221; link_text_align=&#8221;left&#8221; link_text_color=&#8221;#692d87&#8243; link_font_size=&#8221;16px&#8221; header_4_font=&#8221;|600|||||||&#8221; header_4_text_align=&#8221;left&#8221; header_4_text_color=&#8221;#692d87&#8243; header_4_font_size=&#8221;20px&#8221; background_image=&#8221;https:\/\/aafa.org\/wp-content\/uploads\/2022\/06\/scribble.png&#8221; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; global_module=&#8221;5192&#8243; saved_tabs=&#8221;all&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4>Support Our Work<\/h4>\n<p><span data-teams=\"true\">AAFA is fighting to protect life-saving research and programs that are critical for the health of our asthma and allergy community. We need your support.<\/span><\/p>\n<p><a href=\"\/get-involved\/make-a-donation\/\">Donate Today &gt;<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Blog Feed Section&#8221; module_class=&#8221;int-blog-ftr&#8221; _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#F5EDDF&#8221; custom_margin=&#8221;||||false|false&#8221; custom_padding=&#8221;2%||2%||false|false&#8221; top_divider_color=&#8221;#28BDBA&#8221; top_divider_flip=&#8221;horizontal&#8221; bottom_divider_color=&#8221;#28BDBA&#8221; bottom_divider_height=&#8221;50px&#8221; bottom_divider_arrangement=&#8221;above_content&#8221; global_module=&#8221;9328&#8243; saved_tabs=&#8221;all&#8221; collapsed=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text admin_label=&#8221;Related Content&#8221; _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#505050&#8243; link_font=&#8221;||||on|||#008c99|&#8221; link_text_color=&#8221;#008c99&#8243; header_2_font=&#8221;|600|||||||&#8221; header_2_text_color=&#8221;#008c99&#8243; header_2_font_size=&#8221;39px&#8221; header_3_font=&#8221;|600|||||||&#8221; header_3_text_align=&#8221;left&#8221; header_3_text_color=&#8221;#008c99&#8243; header_3_font_size=&#8221;28px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h3>Related Content<\/h3>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_3,1_3,1_3&#8243; use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;2&#8243; disabled_on=&#8221;off|off|off&#8221; _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||1%||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/aafa.org\/wp-content\/uploads\/2023\/05\/health-equity-heal-year2-launch-BT.png&#8221; alt=&#8221;Chick-fil-A product change alert&#8221; title_text=&#8221;health-equity-heal-year2-launch-BT&#8221; show_bottom_space=&#8221;off&#8221; align=&#8221;center&#8221; _builder_version=&#8221;4.20.4&#8243; _module_preset=&#8221;default&#8221; background_enable_image=&#8221;off&#8221; width=&#8221;100%&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_text admin_label=&#8221;Blog Link Text&#8221; _builder_version=&#8221;4.20.4&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;|600|||||||&#8221; text_text_color=&#8221;#28BDBA&#8221; text_font_size=&#8221;16px&#8221; text_line_height=&#8221;1.6em&#8221; link_font=&#8221;|600|||||||&#8221; link_text_align=&#8221;left&#8221; link_text_color=&#8221;#28BDBA&#8221; link_font_size=&#8221;16px&#8221; link_line_height=&#8221;1.6em&#8221; background_color=&#8221;#FFFFFF&#8221; height=&#8221;105px&#8221; custom_padding=&#8221;5%|4%|4%|8%|false|false&#8221; global_colors_info=&#8221;{}&#8221; text_text_color__hover_enabled=&#8221;on|hover&#8221; text_text_color__hover=&#8221;#28BDBA&#8221; link_text_color__hover_enabled=&#8221;on|hover&#8221; link_text_color__hover=&#8221;#692D87&#8243;]<\/p>\n<p><a href=\"https:\/\/community.aafa.org\/blog\/aafa-expands-heal-program-to-further-serve-communities-facing-health-inequities\" target=\"_blank\" rel=\"noopener\">AAFA Expands HEAL Program to Further Serve Communities Facing Health Inequities<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/aafa.org\/wp-content\/uploads\/2022\/10\/asthma-care-for-adults-BT-1.png&#8221; alt=&#8221;Lunch Box hacks&#8221; title_text=&#8221;asthma-care-for-adults-BT&#8221; show_bottom_space=&#8221;off&#8221; align=&#8221;center&#8221; _builder_version=&#8221;4.19.0&#8243; _module_preset=&#8221;default&#8221; background_enable_image=&#8221;off&#8221; width=&#8221;100%&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_text admin_label=&#8221;Blog Link Text&#8221; _builder_version=&#8221;4.20.4&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;|600|||||||&#8221; text_text_color=&#8221;#28BDBA&#8221; text_font_size=&#8221;16px&#8221; text_line_height=&#8221;1.6em&#8221; link_font=&#8221;|600|||||||&#8221; link_text_align=&#8221;left&#8221; link_text_color=&#8221;#28BDBA&#8221; link_font_size=&#8221;16px&#8221; link_line_height=&#8221;1.6em&#8221; background_color=&#8221;#FFFFFF&#8221; height=&#8221;105px&#8221; custom_padding=&#8221;5%|4%|4%|8%|false|false&#8221; global_colors_info=&#8221;{}&#8221; text_text_color__hover_enabled=&#8221;on|hover&#8221; text_text_color__hover=&#8221;#28BDBA&#8221; link_text_color__hover_enabled=&#8221;on|hover&#8221; link_text_color__hover=&#8221;#692D87&#8243;]<\/p>\n<p><a href=\"https:\/\/community.aafa.org\/blog\/new-program-teaches-adults-about-proper-asthma-care\" target=\"_blank\" rel=\"noopener\">A New Free Online Class Can Improve Your Asthma Health<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.17.4&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/aafa.org\/wp-content\/uploads\/2023\/10\/action-alert-BT.png&#8221; alt=&#8221;Milk Allergy Alert&#8221; title_text=&#8221;action-alert-BT&#8221; url=&#8221;https:\/\/community.aafa.org\/blog\/urgent-action-needed-to-protect-our-community&#8221; show_bottom_space=&#8221;off&#8221; align=&#8221;center&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; background_enable_image=&#8221;off&#8221; width=&#8221;100%&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_text admin_label=&#8221;Blog Link Text&#8221; _builder_version=&#8221;4.27.4&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;|600|||||||&#8221; text_text_color=&#8221;#28BDBA&#8221; text_font_size=&#8221;16px&#8221; text_line_height=&#8221;1.6em&#8221; link_font=&#8221;|600|||||||&#8221; link_text_align=&#8221;left&#8221; link_text_color=&#8221;#28BDBA&#8221; link_font_size=&#8221;16px&#8221; link_line_height=&#8221;1.6em&#8221; background_color=&#8221;#FFFFFF&#8221; height=&#8221;105px&#8221; custom_padding=&#8221;5%|4%|4%|8%|false|false&#8221; global_colors_info=&#8221;{}&#8221; text_text_color__hover_enabled=&#8221;on|hover&#8221; text_text_color__hover=&#8221;#28BDBA&#8221; link_text_color__hover_enabled=&#8221;on|hover&#8221; link_text_color__hover=&#8221;#692D87&#8243;]<\/p>\n<p class=\"ai-optimize-6\"><a href=\"https:\/\/community.aafa.org\/blog\/urgent-action-needed-to-protect-our-community\" target=\"_blank\" rel=\"noopener\">Urgent Action Needed to Protect Our Community<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; custom_margin=&#8221;0px||||false|false&#8221; custom_padding=&#8221;0px||0px||true|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text admin_label=&#8221;View More Link&#8221; _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#008C99&#8243; link_font=&#8221;|600||on|||||&#8221; link_text_align=&#8221;right&#8221; link_text_color=&#8221;#008C99&#8243; link_font_size=&#8221;18px&#8221; text_orientation=&#8221;right&#8221; global_colors_info=&#8221;{}&#8221; link_text_color__hover_enabled=&#8221;on|hover&#8221; link_text_color__hover=&#8221;#692D87&#8243;]<\/p>\n<p><a href=\"https:\/\/community.aafa.org\/blog\" target=\"_blank\" rel=\"noopener\">View more blog articles &gt;<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ProgramsThe Asthma and Allergy Foundation of America (AAFA), in collaboration with Medlive, offers a variety of free continuing medical education (CME) programs for health care providers. The programs aim to [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":19433,"parent":8797,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-14238","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.5 (Yoast SEO v28.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Continuing Medical Education (CME) Programs - Asthma and Allergy Foundation of America<\/title>\n<meta name=\"description\" content=\"Get free continuing medical education (CME) credits on asthma and allergies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/aafa.org\/programs\/education-programs\/asthma-allergies-continuing-education-cme\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Continuing Medical Education (CME) Programs\" \/>\n<meta property=\"og:description\" content=\"Get free continuing medical education (CME) credits on asthma and allergies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/aafa.org\/programs\/education-programs\/asthma-allergies-continuing-education-cme\/\" \/>\n<meta property=\"og:site_name\" content=\"Asthma and Allergy Foundation of America\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-23T21:32:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/aafa.org\/wp-content\/uploads\/2024\/04\/continuing-medical-education.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/aafa.org\\\/programs\\\/education-programs\\\/asthma-allergies-continuing-education-cme\\\/\",\"url\":\"https:\\\/\\\/aafa.org\\\/programs\\\/education-programs\\\/asthma-allergies-continuing-education-cme\\\/\",\"name\":\"Continuing Medical Education (CME) Programs - Asthma and Allergy Foundation of America\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/aafa.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/aafa.org\\\/programs\\\/education-programs\\\/asthma-allergies-continuing-education-cme\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/aafa.org\\\/programs\\\/education-programs\\\/asthma-allergies-continuing-education-cme\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/aafa.org\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/continuing-medical-education.png\",\"datePublished\":\"2023-02-22T21:04:44+00:00\",\"dateModified\":\"2026-09-23T21:32:19+00:00\",\"description\":\"Get free continuing medical education (CME) credits on asthma and allergies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/aafa.org\\\/programs\\\/education-programs\\\/asthma-allergies-continuing-education-cme\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/aafa.org\\\/programs\\\/education-programs\\\/asthma-allergies-continuing-education-cme\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/aafa.org\\\/programs\\\/education-programs\\\/asthma-allergies-continuing-education-cme\\\/#primaryimage\",\"url\":\"https:\\\/\\\/aafa.org\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/continuing-medical-education.png\",\"contentUrl\":\"https:\\\/\\\/aafa.org\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/continuing-medical-education.png\",\"width\":1080,\"height\":720,\"caption\":\"A nurse is sitting at a desk in front of computer.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/aafa.org\\\/programs\\\/education-programs\\\/asthma-allergies-continuing-education-cme\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Programs\",\"item\":\"https:\\\/\\\/aafa.org\\\/programs\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Education Programs\",\"item\":\"https:\\\/\\\/aafa.org\\\/programs\\\/education-programs\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Continuing Medical Education (CME) Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/aafa.org\\\/#website\",\"url\":\"https:\\\/\\\/aafa.org\\\/\",\"name\":\"Asthma and Allergy Foundation of America\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/aafa.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Continuing Medical Education (CME) Programs - Asthma and Allergy Foundation of America","description":"Get free continuing medical education (CME) credits on asthma and allergies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/aafa.org\/programs\/education-programs\/asthma-allergies-continuing-education-cme\/","og_locale":"en_US","og_type":"article","og_title":"Continuing Medical Education (CME) Programs","og_description":"Get free continuing medical education (CME) credits on asthma and allergies.","og_url":"https:\/\/aafa.org\/programs\/education-programs\/asthma-allergies-continuing-education-cme\/","og_site_name":"Asthma and Allergy Foundation of America","article_modified_time":"2026-09-23T21:32:19+00:00","og_image":[{"width":1080,"height":720,"url":"https:\/\/aafa.org\/wp-content\/uploads\/2024\/04\/continuing-medical-education.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/aafa.org\/programs\/education-programs\/asthma-allergies-continuing-education-cme\/","url":"https:\/\/aafa.org\/programs\/education-programs\/asthma-allergies-continuing-education-cme\/","name":"Continuing Medical Education (CME) Programs - Asthma and Allergy Foundation of America","isPartOf":{"@id":"https:\/\/aafa.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/aafa.org\/programs\/education-programs\/asthma-allergies-continuing-education-cme\/#primaryimage"},"image":{"@id":"https:\/\/aafa.org\/programs\/education-programs\/asthma-allergies-continuing-education-cme\/#primaryimage"},"thumbnailUrl":"https:\/\/aafa.org\/wp-content\/uploads\/2024\/04\/continuing-medical-education.png","datePublished":"2023-02-22T21:04:44+00:00","dateModified":"2026-09-23T21:32:19+00:00","description":"Get free continuing medical education (CME) credits on asthma and allergies.","breadcrumb":{"@id":"https:\/\/aafa.org\/programs\/education-programs\/asthma-allergies-continuing-education-cme\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/aafa.org\/programs\/education-programs\/asthma-allergies-continuing-education-cme\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/aafa.org\/programs\/education-programs\/asthma-allergies-continuing-education-cme\/#primaryimage","url":"https:\/\/aafa.org\/wp-content\/uploads\/2024\/04\/continuing-medical-education.png","contentUrl":"https:\/\/aafa.org\/wp-content\/uploads\/2024\/04\/continuing-medical-education.png","width":1080,"height":720,"caption":"A nurse is sitting at a desk in front of computer."},{"@type":"BreadcrumbList","@id":"https:\/\/aafa.org\/programs\/education-programs\/asthma-allergies-continuing-education-cme\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Programs","item":"https:\/\/aafa.org\/programs\/"},{"@type":"ListItem","position":2,"name":"Education Programs","item":"https:\/\/aafa.org\/programs\/education-programs\/"},{"@type":"ListItem","position":3,"name":"Continuing Medical Education (CME) Programs"}]},{"@type":"WebSite","@id":"https:\/\/aafa.org\/#website","url":"https:\/\/aafa.org\/","name":"Asthma and Allergy Foundation of America","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/aafa.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/aafa.org\/wp-json\/wp\/v2\/pages\/14238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aafa.org\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/aafa.org\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/aafa.org\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/aafa.org\/wp-json\/wp\/v2\/comments?post=14238"}],"version-history":[{"count":100,"href":"https:\/\/aafa.org\/wp-json\/wp\/v2\/pages\/14238\/revisions"}],"predecessor-version":[{"id":34033,"href":"https:\/\/aafa.org\/wp-json\/wp\/v2\/pages\/14238\/revisions\/34033"}],"up":[{"embeddable":true,"href":"https:\/\/aafa.org\/wp-json\/wp\/v2\/pages\/8797"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aafa.org\/wp-json\/wp\/v2\/media\/19433"}],"wp:attachment":[{"href":"https:\/\/aafa.org\/wp-json\/wp\/v2\/media?parent=14238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}